BRCA1 is an inclusion eligibility criterion in 2 clinical trials for ovarian endometrioid tumor, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 status and ovarian endometrioid tumor as inclusion criteria, 1 is phase 2/phase 3 (1 open) and 1 is phase 3 (1 open) [3].

BRCA2 is an inclusion eligibility criterion in 2 clinical trials for ovarian endometrioid tumor, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and ovarian endometrioid tumor as inclusion criteria, 1 is phase 2/phase 3 (1 open) and 1 is phase 3 (1 open) [3].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for ovarian endometrioid tumor, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and ovarian endometrioid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for ovarian endometrioid tumor, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and ovarian endometrioid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for ovarian endometrioid tumor, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and ovarian endometrioid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for ovarian endometrioid tumor, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and ovarian endometrioid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].